Multiple primary cancers in patients with osteosarcoma - Influence of anticancer drugs and genetic factors

被引:10
作者
Yonemoto, T [1 ]
Tatezaki, S [1 ]
Ishii, T [1 ]
Hagiwara, Y [1 ]
Inoue, M [1 ]
机构
[1] Natl Chiba Higashi Hosp, Div Orthopaed Surg, Chuo Ku, Chiba 2608717, Japan
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2004年 / 27卷 / 03期
关键词
osteosarcoma; multiple primary cancers; chemotherapy; germ-line p53 gene mutation;
D O I
10.1097/01.COC.0000054534.43117.76
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
One hundred thirty-five patients younger than 30 years with osteosarcoma were treated at the Chiba Cancer Center between 1976 and 1999. They included six patients with second cancer after cure of osteosarcoma (group A) and three patients with osteosarcoma as second cancer after cure of childhood cancers (group B). Third cancer occurred in one patient of group A. The clinical features of these nine patients were studied. The diagnoses of second cancer in group A consisted of two acute myelogenous leukemias, two breast carcinomas, one malignant phyllodes tumor of breast, and one ovarian carcinoma. The third cancer was uterine leiomyosarcoma. Second cancer occurred an average of 7.2 years after occurrence of osteosarcoma. The diagnoses of first cancer in group B consisted of one adrenocortical carcinoma, one malignant teratoma of sacrum, and one ovarian carcinoma (yolk sac tumor). Osteosarcoma occurred on average 12.7 years after occurrence of first cancer. Two patients had germ-line p53 gene mutation. Anticancer drugs and genetic factors are presumed to be concerned with occurrence of second cancer. The frequency of multiple primary cancers in patients with osteosarcoma is by no means low. Strict follow-up is thus needed over a long period.
引用
收藏
页码:220 / 224
页数:5
相关论文
共 34 条
[1]   OSTEOSARCOMA AS A 2ND MALIGNANT NEOPLASM IN CHILDREN [J].
BECHLER, JR ;
ROBERTSON, WW ;
MEADOWS, AT ;
WOMER, RB .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1992, 74A (07) :1079-1083
[2]   Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome [J].
Bell, DW ;
Varley, JM ;
Szydlo, TE ;
Kang, DH ;
Wahrer, DCR ;
Shannon, KE ;
Lubratovich, M ;
Verselis, SJ ;
Isselbacher, KJ ;
Fraumeni, JF ;
Birch, JM ;
Li, FP ;
Garber, JE ;
Haber, DA .
SCIENCE, 1999, 286 (5449) :2528-2531
[3]   Combined modality treatment for osteosarcoma occurring as a second malignant disease [J].
Bielack, SS ;
Kempf-Bielack, B ;
Heise, U ;
Schwenzer, D ;
Winkler, K .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1164-1174
[4]  
BURKE E, 1991, CANCER-AM CANCER SOC, V67, P1467, DOI 10.1002/1097-0142(19910301)67:5<1467::AID-CNCR2820670535>3.0.CO
[5]  
2-4
[6]  
Carnevale A, 1997, ARCH MED RES, V28, P383
[7]  
Chauveinc L, 2001, Ophthalmic Genet, V22, P77, DOI 10.1076/opge.22.2.77.2228
[8]   2ND PRIMARY NEOPLASMS IN PATIENTS WITH RETINOBLASTOMA [J].
DRAPER, GJ ;
SANDERS, BM ;
KINGSTON, JE .
BRITISH JOURNAL OF CANCER, 1986, 53 (05) :661-671
[9]  
Enneking WF, 1980, CLIN ORTHOP RELAT R, V153, P106
[10]   Secondary tumors in bone sarcomas after treatment with chemotherapy [J].
Ferrari, C ;
Bohling, T ;
Benassi, MS ;
Ferraro, A ;
Gamberi, G ;
Bacci, G ;
del Prever, AB ;
Sangiorgi, L ;
Ragazzini, P ;
Sollazzo, MR ;
Balladelli, A ;
Picci, P .
CANCER DETECTION AND PREVENTION, 1999, 23 (05) :368-374